Insulin-like growth factor-1 and insulin-like growth factor binding protein-3 as early predictors of growth, body composition, and neurodevelopment in preterm infants

Megan E Paulsen; Nicholas Marka; Scott Lunos; Emily M Nagel; Juan David Gonzalez Villamizar; Brandon Nathan; Sara Ramel

doi:10.1038/s41372-024-01933-3

Insulin-like growth factor-1 and insulin-like growth factor binding protein-3 as early predictors of growth, body composition, and neurodevelopment in preterm infants

J Perinatol. 2024 Apr 1. doi: 10.1038/s41372-024-01933-3. Online ahead of print.

Authors

Megan E Paulsen^{1

2

3}, Nicholas Marka⁴, Scott Lunos⁴, Emily M Nagel⁵, Juan David Gonzalez Villamizar^{6

7}, Brandon Nathan⁸, Sara Ramel^{6

9}

Affiliations

¹ Division of Neonatology, Department of Pediatrics, University of Minnesota Medical School, Minneapolis, MN, USA. megan.paulsen@childrensmn.org.
² Children's Minnesota, Minneapolis, MN, USA. megan.paulsen@childrensmn.org.
³ Masonic Institute for the Developing Brain, University of Minnesota, Minneapolis, MN, USA. megan.paulsen@childrensmn.org.
⁴ Biostatistical Design and Analysis Center, Clinical Translational Science Institute, University of Minnesota, Minneapolis, MN, USA.
⁵ University of Minnesota School of Public Health, Minneapolis, MN, USA.
⁶ Division of Neonatology, Department of Pediatrics, University of Minnesota Medical School, Minneapolis, MN, USA.
⁷ Children's Minnesota, Minneapolis, MN, USA.
⁸ Division of Endocrinology, Department of Pediatrics, University of Minnesota Medical School, Minneapolis, MN, USA.
⁹ Masonic Institute for the Developing Brain, University of Minnesota, Minneapolis, MN, USA.

PMID: 38561392
DOI: 10.1038/s41372-024-01933-3

Abstract

Objective: To investigate the relationship between insulin-like growth factor 1 (IGF-1), insulin-like growth factor binding protein 3 (IGFBP-3) and long-term growth, body composition, and neurodevelopment in preterm infants.

Study design: Prospective data were collected from ≤32 weeks gestational age infant cohort (N = 50). IGF-1 and IGFBP-3 concentrations were measured at 1 week (early) and 35 weeks (late) post-menstrual age (PMA). Growth, body composition, and neurodevelopment outcomes were measured at 4 and 12 months PMA. Relationships were measured by linear regression analysis.

Results: Early IGFBP-3 concentration was positively associated with neurodevelopment at 12 months PMA. Early IGF-1 concentration was positively associated with weight at 4 months PMA, head circumference at 12 months PMA, and body mass index at 12 months PMA. Late IGFBP-3 concentration was positively associated with weight at 4 months PMA.

Conclusion: Further investigation of these associations may lead to novel biomarkers and/or treatments to optimize health outcomes in preterm infants.

Abstract

Grants and funding